ABBV Updates Full-Year 2026 EPS Guidance to $13.76-$13.96, Citing $216M Q3 IPR&D Expense
· The NYC Memo
AbbVie Inc. reported preliminary third quarter 2026 GAAP and adjusted diluted EPS would be unfavorably impacted by $0.11 due to a $216 million pre-tax acquired IPR&D and milestones expense. The company updated its full-year 2026 adjusted diluted EPS guidance range to $13.76-$13.96 and provided a third-quarter 2026 adjusted diluted EPS guidance range of $3.73-$3.77, both reflecting this expense.